Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Next Previous
Trial Profile

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galinpepimut S (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Expanded access; Therapeutic Use
  • Sponsors Sellas Life Sciences Group

Most Recent Events

  • 29 Apr 2022 New trial record
  • 26 Apr 2022 According to a Sellas Life Sciences Group media release, company has launched a Pre-Approval Access/Expanded Access Program with GPS for treating patients suffering from acute myeloid leukemia (AML).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top